Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice

Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice

Parkinson’s disease (PD) is a progressive neurological disorder estimated to affect 7–10 million people worldwide. There is no treatment available that cures or slows the progression of PD. Elevated leucine-rich repeat kinase 2 (LRRK2) activity has been associated with genetic and sporadic forms of...

Full description

Bibliographic Details
Main Authors: Joanna A. Korecka, Ria Thomas, Anthony J. Hinrich, Alyssa M. Moskites, Zach K. Macbain, Penelope J. Hallett, Ole Isacson, Michelle L. Hastings
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
LRRK2
antisense oligonucleotide
Parkinson’s disease
LRRK2 BAC mice
splicing
RAB10
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253120301888

Internet

http://www.sciencedirect.com/science/article/pii/S2162253120301888

Similar Items